EUCTR2005-005452-41-GB进行中（未招募）1 期
A phase III Multicenter, randomised, parallel, placebo-controlled, double-blind study to investigate the safety and efficacy of treatment with Bronchitol (dry powder mannitol) in the symptomatic treatment of bronchiectasis.
Pharmaxis UK Limited0 个研究点目标入组 354 人开始时间: 2006年4月10日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 354
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •(1) Evidence of confirmed diagnosis of (non CF) bronchiectasis by HRCT (2) Age: 15 – 80 years inclusive (3) FEV1 50% - 80% predicted and =1.0L (4) Chronic cough (defined as persistently troublesome cough present on the majority of days in the 3 months prior to enrolment) (5) Chronic sputum production of >10 mL per day on the majority of days in the 3 months prior to study entry (6) Chronic chest congestion ( defined as chronic excessive accumulation of mucus in the lungs) (7) Ability to perform all the techniques necessary to measure lung function, and (8) Stable clinical condition at the time of, and for a period of 14 days prior to recruitment; defined as lack of: (a) change in techniques for sputum clearance (b) change in sputum production (volume, colour, consistency) (c) new or increased haemoptysis (d) increased cough (e) worsening dyspnoea (f) increased malaise, fatigue or lethargy (g) reduction in exercise tolerance (h) fever (g) increase in weight loss or anorexia (h) sinus pain/tenderness or change in sinus discharge (i) gastrointestinal symptoms such as diarrhoea, constipation, nausea, vomiting or (j) additional antibiotics (routine antibiotics permitted)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •(1) Investigators, site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted (2) Bronchiectasis as a consequence of cystic fibrosis or focal endobronchial lesion (3) Terminally ill” patients or those listed for transplantation (4) Use of hypertonic saline or mucolytic pharmacological agents concurrently or in the 4 weeks prior to study entry (5) Patients previously enrollment in a clinical trial using Bronchitol that was administered for more than a day (6) Significant episode of haemoptysis (>60 mL) in the previous 6 months (7) Exacerbation for which intravenous antibiotics were prescribed in the 4 weeks prior to study entry (8) Presence of airway hyperresponsiveness as defined by a positive Aridol challenge (9) Smoking history of >10 pack years or if more than 1 cigarette smoked per week within the previous 3 months (10) Likeliness of developing bronchoconstriction in response to Bronchitol in the opinion of the investigator (11) Myocardial Infarction in the three months prior to enrolment (12) Cerebral vascular accident in the three months prior to enrolment (13) Major ocular surgery in the three months prior to enrolment (14) Major abdominal, chest or brain surgery in the three months prior to enrolment (15) Presence of cerebral, aortic or abdominal aneurysm (16) Active tuberculosis (17) Active malignancy including melanoma (other skin carcinomas and remissions exempted) (18) Females who are breast feeding or pregnant or plan to become pregnant during the study (19) At risk females unwilling to use appropriate contraception to prevent pregnancy during the study (20) Patients participating in another investigative drug study, parallel to, or within 4 weeks of study entry (21) Known intolerance to mannitol or ß-agonists (22) Uncontrolled hypertension – systolic BP > 190 and or diastolic BP > 100 or (23) Patient has a condition or is in a situation which in the Investigator’s opinion may put the subject at significant risk, may confound results or may interfere significantly with participation in the study
研究者
相似试验
进行中（未招募）
1 期
A phase III multicentre, randomized, parallel, controlled, double blind study to investigate the safety and efficacy of inhaled mannitol over 12 months in the treatment of bronchiectasis. - DPM-B-305 Inhaled Mannitol in BronchiectasisBronchiectasisEUCTR2008-008731-28-GBPharmaxis Pharmaceuticals Limited474
进行中（未招募）
不适用
A phase III multicenter, randomized, parallel, controlled, double blind study to investigate the safety and efficacy of inhaled mannitol over 12 months in the treatment of bronchiectasis.MedDRA version: 9.1Level: LLTClassification code 10006445Term: BronchiectasisBronchiectasisEUCTR2008-008731-28-NLPharmaxis Ltd.474
进行中（未招募）
1 期
A phase III multicenter, randomized, parallel, controlled, double blind study to investigate the safety and efficacy of inhaled mannitol over 12 months in the treatment of bronchiectasis.BronchiectasisEUCTR2008-008731-28-BEPharmaxis Ltd.474
进行中（未招募）
不适用
A phase III multicenter, randomized, parallel, controlled, double blind study to investigate the safety and efficacy of inhaled mannitol over 12 months in the treatment of bronchiectasisMedDRA version: 9.1Level: LLTClassification code 10006445Term: BronchiectasisBronchiectasisEUCTR2008-002644-42-GBPharmaxis Pharmaceuticals Limited400
已完成
3 期
A phase III multicenter, randomized, parallel, controlled, double blind study to investigate the safety and efficacy of inhaled mannitol over 12 months in the treatment of bronchiectasis.Bronchiectasis10006436NL-OMON34341Pharmaxis Ltd25